Compare · CNC vs NTRA
CNC vs NTRA
Side-by-side comparison of Centene Corporation (CNC) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $30.84B, about the same size as CNC ($30.78B).
- NTRA has been more active in the news (16 items in the past 4 weeks vs 6 for CNC).
- Both have 25 recent analyst ratings on file.
- Company
- Centene Corporation
- Natera Inc.
- Price
- $62.31-0.59%
- $215.31-3.06%
- Market cap
- $30.78B
- $30.84B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 6
- 16
- Recent ratings
- 25
- 25
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest CNC
- SEC Form 4 filed by Group President, Medicare&Spec Carson Michael A
- Five Stars: Health Net Recognized by USA TODAY for Customer Service; Only California-Based Health Insurer Recognized with Highest Rating
- SEC Form 4 filed by Group President, Medicare&Spec Carson Michael A
- Centene upgraded by Deutsche Bank with a new price target
- New insider Finke Daniel P claimed ownership of 228,127 shares (SEC Form 3)
- New insider Carson Michael A claimed ownership of 123,707 shares (SEC Form 3)
- Centene Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update
- Director Tanji Kenneth was granted 3,992 shares, increasing direct ownership by 50% to 11,909 units (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 3,992 shares, increasing direct ownership by 19% to 24,748 units (SEC Form 4)
- Director Ford Monte E was granted 3,992 shares, increasing direct ownership by 37% to 14,827 units (SEC Form 4)
Latest NTRA
- CEO AND PRESIDENT Chapman Steven Leonard sold $9,089,776 worth of shares (41,124 units at $221.03) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 108,743 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $655,295 worth of shares (3,000 units at $218.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 137,643 units (SEC Form 4)
- Director Rubin Eric H was granted 2,124 shares, increasing direct ownership by 42,480% to 2,129 units (SEC Form 4)
- Director Botha Roelof sold $17,184,092 worth of shares (78,000 units at $220.31) (SEC Form 4)
- Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
- Wolfe Research resumed coverage on Natera with a new price target
- SEC Form 144 filed by Natera Inc.
- Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma